IQVIA groups up with French pharma Servier to ‘reinvent scientific growth’


Servier is searching for a significant R&D transformation and is tapping contract analysis group IQVIA to assist.

Setting out its so-called Servier Medical Operations REinvent (SCORE) program, the French pharma is trying “optimize scientific trial purposes, enterprise processes, group and governance.” To this finish, it’s asking IQVIA to “help Servier on course of and group streams and on change and program administration.”

This comes as Servier has this yr regarded to beef up its pipeline, and in April it snapped up Danish most cancers biotech Symphogen to bolster its immuno-oncology R&D, constructing on its latest pact with Cellectis and its cell therapies.

Sponsored by Medidata

Your Information to Maximizing the Advantages of a Unified Medical Knowledge Seize and Administration Platform

Find out how a unified platform can improve visibility throughout your trial. Undertake expertise options driving sooner, extra correct knowledge interpretation for higher decision-making to stay aggressive in a brand new period of drug growth.

It’s made no secret of its need to turn into a acknowledged participant in oncology, one thing that may little question even be helped by its $2.four billion purchase of Shire’s most cancers biz in 2018, itself coming after the Irish-based pharma was subsumed into Takeda.

“The SCORE program is an R&D initiative that drives digital and enterprise transformation, accelerates scientific growth, enhances drug candidate worth and higher addresses unmet medical wants whereas bettering affected person outcomes,” stated Patricia Belissa-Mathiot, director of scientific growth and R&D CMO at Servier.

“SCORE additionally will increase collaboration, insights and affected person centricity by its lean end-to-end processes, streamlined group, use of data-driven insights, standardization and environment friendly expertise.”

RELATED: IQVIA nudges up steering on bullish outlook, however R&D providers nonetheless dragging on COVID-19 challenges

IQVIA, which got here out of the merger of Quintiles and IMS, is in a lot demand, working trials for AstraZeneca and the College of Oxford’s late-stage COVID-19 vaccine. It has spent a lot of the yr battling the results of the pandemic on its enterprise.

In its third-quarter financials, the CRO stated it’s nonetheless steering round COVID-19 roadblocks with its R&D enterprise nonetheless posting a loss, however different segments are recovering because it upped its full-year steering.

Within the new collab, financials of which weren’t shared, IQVIA will probably be tapped over the subsequent two years to assist Servier SCORE.

“We’re delighted to have been chosen by Servier to ship on their R&D agenda. IQVIA’s distinctive mixture of capabilities and progressive method will help Servier’s ambitions via the SCORE mission,” added Alistair Grenfell, president of Europe, Center East, Africa and South Asia for IQVIA.


Please enter your comment!
Please enter your name here